Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 63Neoplasms 5Neoplasm Metastasis 5Carcinoma, Intraductal, Noninfiltrating 3Breast Neoplasms, Male 3Recurrence 2Ovarian Neoplasms 2Endometrial Neoplasms 2Breast Diseases 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Tuberous Sclerosis 1Squamous Cell Carcinoma of Head and Neck 1Sexual Dysfunctions, Psychological 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms by Site 1Multiple Endocrine Neoplasia Type 1 1Locoregional Recurrence 1Hyperglycemia 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1Granulosa cell tumor of the ovary 1Endometrial Stromal Tumors 1Endometrial Hyperplasia 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 69Nivolumab 67cabozantinib 45Ipilimumab 36Specimen Handling 32Magnetic Resonance Spectroscopy 32lenvatinib 26Axitinib 25belzutifan 21Sunitinib 17Biopsy 15Radiosurgery 14CTLA-4 Antigen 13atezolizumab 12Everolimus 10pazopanib 8fludarabine 8avelumab 8Bevacizumab 8toripalimab 7cemiplimab 7Nephrectomy 7Immunoglobulin G 7Cyclophosphamide 7aldesleukin 6Standard of Care 6Radiotherapy 6Blood Specimen Collection 6spartalizumab 5palbociclib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × exemestane × 1 year × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡